ArticleDiabetologia2014
Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment.
Article in Diabetologia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Pooled it
- Hyperglycemia during ICI Therapy: etiology, risk factors, and survival outcome.Journal of endocrinological investigation · 2026Article
- The impact of diabetes on clinical outcomes in acutely ill patients - a study on patients admitted to the emergency department.BMC cardiovascular disorders · 2026Article
- Glucagon-like peptide-1 receptor agonists are associated with cardiac, cancer- and mortality-related benefits in diabetic patients treated with anthracyclines.European heart journal open · 2026Article
- GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization.The Journal of clinical endocrinology and metabolism · 2026Article
- Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period.Journal of managed care & specialty pharmacy · 2026Article
- J-shaped associations of serum urate with all-cause and cause-specific mortality in diabetes: mediation by kidney function.Acta diabetologica · 2026Article
- Impact of coexisting diabetes on the development of cardiovascular disease and death in patients with cancer.PloS one · 2026Article
- Interconnected Mechanistic Pathways, Molecular Biomarkers, and Therapeutic Approach of Oral Cancer in Patients with Diabetes Mellitus.Current issues in molecular biology · 2025Review
- Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab.Medicina (Kaunas, Lithuania) · 2025Article
- Add-On Treatment with Gliclazide for Cancer Patients with Type 2 Diabetes Undergoing Cyclic Glucocorticoid-Containing Chemotherapy.Biomedicines · 2025Article
- Synergistic impact of dysglycemia and HPV on cervical cancer risk: a potential mediating role of Ki-67.Frontiers in endocrinology · 2025Article
- Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view.Journal of endocrinological investigation · 2024Review
- The association of diabetes mellitus and routinely collected patient-reported outcomes in patients with cancer. A real-world cohort study.Cancer medicine · 2024Article
- Health Care Use Among Cancer Patients With Diabetes, National Health and Nutrition Examination Survey, 2017-2020.Preventing chronic disease · 2024Article
- Socioeconomic disparity in stage at cancer diagnosis among patients with type 2 diabetes in Dutch primary care: a cross-sectional study.BMJ public health · 2024Article
- Degree of joint risk factor control and hazard of mortality in diabetes patients: a matched cohort study in UK Biobank.BMC medicine · 2024Article
- Effect of metformin on outcomes of patients treated with immune checkpoint inhibitors: a retrospective cohort study.Cancer immunology, immunotherapy : CII · 2023Article
- The impact of peroxisome proliferator-activated receptor-γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy.Cancer medicine · 2023Article
- The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisThe prognostic role of different diabetes treatment types has not been studied in detail. We compared mortality rates among cancer patients with and without diabetes, accounting for diabetes treatment and diabetes duration.
methodsThis register-based study included all cancer patients diagnosed in Denmark during 1995-2009. The patients were classified into four groups according to diabetes status at the time of cancer diagnosis: no diabetes, diabetes without medication, diabetes with only oral hypoglycaemic agent (OHA) or diabetes with insulin treatment. Poisson models were used to examine the association between pre-existing diabetes in cancer patients and mortality relative to the non-diabetic cancer population.
resultsAmong 426,129 patients with incident cancer, we identified 42,205 patients with diabetes prior to cancer diagnosis. Overall, cancer patients with diabetes had higher mortality rates than non-diabetic cancer patients, highest among OHA- or insulin-treated patients. For all cancers combined and diabetes duration of 2 years at cancer diagnosis, insulin-treated patients experienced the highest mortality rate ratios starting from 3.7 (95% CI 2.7, 5.1) for men and 4.4 (3.1, 6.5) for women 1 year after cancer diagnosis, increasing to 5 (3.5, 7.0) for men and 6.5 (4.2, 9.3) for women 9 years after cancer diagnosis. CONCLUSIONS/
interpretationOur study provides strong evidence that cancer patients with pre-existing diabetes experience higher mortality than cancer patients without diabetes. The higher mortality seen among cancer patients treated with OHAs or insulin is in accordance with the existing evidence that more intensive diabetes treatment reflects a larger degree of comorbidity at the time of cancer diagnosis, and hence poorer survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.